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Summary.-Lymphocyte sensitivity to encephalitogenic factor (EF) was measured
with the macrophage migration inhibition (MMI) test in 60 women with dysplasia or
carcinoma in situ of the cervix, in 10 women with invasive cervical carcinoma, and in
20 women with a variety of benign gynaecological conditions. Significant migration
inhibition with EF (P<0-01) was seen with lymphocytes taken from7/13 (54%) women
with mild and/or moderate dysplasia, from22/47 (47%) women with severe dysplasia
and/or carcinoma in situ, from 6/10 (60%) women with invasive cervical carcinoma
and from 3/20 (15%) women with benign gynaecological conditions.
Autologous serum was seen to abrogate EF-mediated migration inhibition in 3/4
sensitized women with mild and/or moderate dysplasia, in 5/7 sensitized women
with severe dysplasia and/or carcinoma in situ and in 2/3 sensitized women with
invasive cervical carcinoma. Autologous serum from2 sensitized women with benign
gynaecological conditions did not abrogate the response oftheir lymphocytes to EF.
SINCE the original observation by Field
& Caspary (1970) that lymphocytes re-
spond to encephalitogenic factor (EF) in
the macrophage electrophoretic mobility
(MEM) test, there is now evidence to sug-
gest that this response is directed against
a common neoantigen or common neo-
antigens on the tumour cell surface (Cas-
pary & Field, 1971; Dickinson et al., 1973;
Coates & Carnegie, 1975). Similar results
have been reported using the macrophage
migration inhibition (MMI) test (Light et
al., 1975) but this test may be less sensitive
than theMEM test (Hughes & Paty, 1971).
Moreover, there is further evidence that
the lymphocyte response to EF may occur
many years before the clinical appearance
of tumour (Field et al., 1972; Pritchard et
al., 1976). Thus Singer and co-workers
(1975) and Porzsolt et al. (1975) have
shown that a large proportion of women
with premalignant cervical lesions and
carcinoma in situ show a lymphocyte re-
sponse to EF. Furthermore Flavell et al.
(1978), using an animal model, have
demonstrated that about half the rats
withcarcinogen-induceddysplastic hepatic
lesions show a spleen-cell response to
EF in the MMI test. In view of this evi-
dence, it seems possible that the demon-
stration of a cell-mediated immune re-
sponse to EF may prove useful in detect-
ing not only cervical premalignant lesions
but premalignant lesions at other sites.
In the present paper we report on the
incidence of a cell-mediated immune re-
sponse to EF as determined with the MMI
test in women with premalignant and
malignant cervical lesions, and in a group
of women with a variety of benign gynae-
cological conditions. In addition, the
effects ofautologous serum on the lympho-
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cyte response to EF was investigated in
some of the patients.
MATERIALS AND METHODS
Patients.-A total of 60 women with either
dysplasia or carcinoma in situ of the cervix
were selected for study. Diagnosis was made
histologically from punch-biopsy specimens
taken at colposcopy, according to the criteria
described by the R.C.O.G. panel (Govan et al.,
1969) and by W.H.O. (Riotton and Christo-
pherson, 1973). Because of the difficulties
often encounteredindiscriminating histologic-
ally between mild and moderate dysplasia or
severe dysplasia and carcinoma in situ (Koss,
1978) these 2 sets of lesions were grouped to-
gether in the study. When both types of
lesion were present, the more severe was ac-
cepted as representative. The group of 13
women with mild and/or moderate dysplasia
had a mean age of 24 years (range 19-42)
whilst the group of47 women with severe dys-
plasia and/or carcinoma in situ had a mean
age of 33 years (range 18-56). A group of 10
women with invasive cervical carcinoma were
also included in the study; they had a mean
age of 46 years (range 30-65). A group of 20
women with various benign gynaecological
conditions was also included in the study.
Their individual diagnoses are given in Table
I. They had a mean age of 32 years (range
16-59).
MMI test.-Lymphocytes harvested from
peripheral blood (Harris and Ukaejiofo, 1970)
were tested for response to EF using the
direct M:MI test. Full details of this test
system have been given elsewhere (Flavell
and Potter, 1978). Briefly, lymphocytes and
peritoneal-exudate cells from guinea-pigs
stimulated with i.p. liquid paraffin (Rees and
Potter, 1973) were mixed in a ratio of 1:5 and
packed into lOuil capillary tubes. Cut capil-
lary tubes were incubated in Medium 199 con-
taining 10% heat-inactivated foetal calf
serum in the absence or in the presence of 100
,tg of EF for 24 h at 37°C. Duplicate control
wells each containing 3 capillary tubes were
set up for each treatment. Areas of macro-
phage migration were estimated at 24 h, and
the percentage of migration inhibition with
EF calculated. The significance of migration
inhibition was assessed with Student's t test.
A value ofP<0 01 was considered indicative
ofsignificant migration inhibition. The effects
TABLE I.-MMI by lymphocytes from
women with cervical dysplasia, carcinoma
in situ, invasive cervical carcinoma, and
benign gynaecological conditions, in the
presence of EF
Diagnosis
Mild and/or moderate
dysplasia
Severe dysplasia and/or
Ca in situ
Invasive cervical
carcinoma
Benign gynaecological
conditions*
No. (%)
showing
significant
Number MMI
tested (P<0*01)
13 7 (54)
47 22 (47)
10 6 (60)
20 3 (15)
* Patients with the following conditions were used
as controls: first trimester pregnancy (6), large cer-
vical ectropion ("erosion") (5), pelvic inflammatory
disease (5), prolapse (1), anovulation (1), ovarian
cyst (1), and a cervical polyp (1).
of heat-inactivated autologous serum upon
EF-mediated migration inhibition were in-
vestigated by including serum in duplicate
sets of wells at a concentration of 10% with
and without EF in the medium.
RESULTS
MMI with EF
Table I shows the number of women
from each group whose lymphocytes
showed significant migration inhibition in
the presence of EF. The percentage of
migration inhibition with EF seen for each
individual is presented as a scatter-graph
in the Fig. Of the 13 women classified as
mild and/or moderate dysplasia, 7 (54%)
showed a response to EF; and of 47
women classified as severe dysplasiaand/or
carcinoma in situ, 22 (47%) showed a
lymphocyte response to EF. Lymphocytes
from 6/10 (60%) women with invasive
cervical carcinoma gave significant migra-
tion inhibition with EF. Of the 20 women
with benign gynaecological conditions, 3
(15%) showed significant migration inhibi-
tion with EF. There was one woman with
a cervical erosion, one woman with chronic
cervicitis and one woman in the first
trimester of pregnancy.
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FiG. Percentage of significant (0) and non-
significant ( 0) macrophage migration inhi-
bition with EF by lymphocytes from
women with cervical dysplasia, carcinoma
in situ, invasive cervical carcinoma and
women with benign gynaecological condi-
tions.
Serum inhibition of MMI
The effects of autologous serum upon
EF-mediated migration inhibition were
investigated in 25 of the women with dys-
plasia and/or carcinoma in situ, in 7
women with invasive cervical carcinoma,
and 9 women with benign gynaecological
conditions. The results are shown in Table
TI. Of the 4 women investigated in the
mild and/or moderate-dysplasia group, 3
showed significant migration inhibition
with EF in the absence of serum, whilst in
the presence of autologous serum only 1
TABLE II.-MMI by lymphocytes from
women with cervical dysplasia, carcinoma
in situ, invasive cervical carcinoma and
benign gynaecological conditions, in the
presenceofEFwithandwithoutautologous
serum
Diagnosis
Mild and/or moderate
dysplasia
Severe dysplasia and/or
Ca in situ
Invasive cervical
carcinoma
Benign gynaecological
conditions*
No. (%) showing
significant
MMI (P<O-O1)
No. Without With
tested serum serum
4 3 (75) 1 (25)
21 7 (33) 3 (14)
7 3 (43) 1 (14)
9 2 (22) 3 (33)
* Group includes: 4 cases with cervical ectropion
(erosions) and 5 with pelvic inflammatory disease.
showed such a response. Of the 21 women
investigated in the severe dysplasia and/or
carcinoma in situ group, 7 showed signi-
ficant migration inhibition with EF in the
absence of serum, whilst in the presence of
autologous serum this response was
abolished in 5 of them. However, autolo-
gous serum from one woman in this group
increased the observed migration-inhibi-
tion response to EF from a non-significant
level in the absence of serum to a signifi-
cant level in the presence of serum. Of the
7 women investigated with invasive cer-
vical carcinoma, 3 showed significant mi-
gration inhibition with EF in the absence
of serum, whilst in the presence of serum
this response was abolished in 2 of them.
Autologous serum from 2 sensitizedwomen
with benign gynaecological conditions did
not abrogate the response oftheir lympho-
cytes to EF. However, it was observed
that autologous serum from one woman
with cervical squamous metaplasia in-
creased the observed migration inhibition
response to EF from a non-significant level
in the absence of serum to a significant
level in the presence of serum.
COMMENT
The results of the present study clearly
demonstrate that a large proportion of
I
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women with premalignant cervical lesions
show a demonstrable lymphocyte response
to EF when tested with the MMI test.
Singer and his associates (1975), using the
MMI test, also demonstrated that 70% of
women with carcinoma in situ and 42% of
women with dysplasia showed a lympho-
cyte response to EF, and sensitization to
EF has been demonstrated in other malig-
nant diseases, using the same test (Shelton
et al. 1975; Light et al., 1975). The inci-
dence of lymphocyte response to EF
observed in the present study was lower
than that reported by Singer and co-
workers (1975). This discrepancy may be
due to differences in the classification
system employed in the 2 studies; in the
present study, women with mild and
moderate dysplasia and those with severe
dysplasia and carcinoma in situ were
grouped together.
The observed incidence of lymphocyte
response to EF in women with premalig-
nant cervical lesions is considerably higher
than for that in women with a variety of
benign gynaecological conditions, and is
about the same as that in women with
invasive cervical carcinoma. A recent
report by Flavell & Potter (1978) has
shown that lymphocytes from 63% of
cancer patients studied respond to EF in
the MMI test, whilst lymphocytes from
32% of individuals with a variety of non-
malignant conditions showed a similar
response. Thus, the incidence of lympho-
cyte response to EF seen in women
with premalignant cervical lesions falls
about halfway between those seen in
cancer patients and patients with benign
conditions.
Caspary & Field (1971), using the macro-
phage electrophoretic mobility (MEM)
test, have demonstrated that lymphocytes
from cancer patients not only respond to
EF, but also to an acid extract of malig-
nant tissues termed "cancer basic protein"
(CaBP). Further studies have shown that
EF and CaBP have remarkable chemical
similarities (Dickinson & Caspary, 1973)
and it has been suggested that the EF and
CaBP molecules share common antigenic
determinants (Coates & Carnegie, 1975;
McDermott et al., 1974; Flavell & Potter,
1978). This has led to the proposal that
the lymphocyte response to EF in malig-
nant disease might represent a cell-
mediated immune response directed
against neoantigens on the tumour-cell
surface which share an antigenic deter-
minant or determinants with EF. Thus,
it is conceivable that the lymphocyte re-
sponse to EF seen in women with pre-
malignant lesions may be due to the
appearance of a neoantigen or neoantigens
on the dysplastic epithelial cell surface,
which is immunologically cross-reactive
with EF; indeed, the appearance of a
lymphocyte response to EF in these
women may prove to be an indicator of
the malignant potential of these lesions.
Serum from most of the women with
cervical dysplasia and carcinoma in situ
who showed a lymphocyte response to EF
abolished this response in vitro. Flavell &
Potter (1978) have recently shown that
serum from most cancer patients showing
lymphocyte response to EF is capable of
abolishing EF-mediated migration inhibi-
tion. Similarly, serum flow patients with
non-malignant conditions who showed a
lymphocyte response to EF, abolished
this response in about half of these indi-
viduals. However, it is difficult to make a
direct comparison between the incidence
of serum abrogation of the lymphocyte
response to EF seen in the present study
and that seen by Flavell & Potter (1978),
in view ofthe small number ofwomen with
cervical dysplasia and carcinoma in situ
investigated in the present study. How-
ever, this preliminary investigation sug-
gests that women with premalignant
cervical lesions might show a similar
incidence of serum abrogation of the
lymphocyte response to EF to that
seen in cancer patients. Field & Caspary
(1972) have shown that a component(s)
present in serum from cancer patients is
capable of depressing the lymphocyte re-
sponse to EF and CaBP in the MEM test.
Further studies have shown that the C2
macroglobulin component of serum is
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responsible for this depression (Ford et al.,
1973). Furthermore, studies by Bernard &
Lamoureux (1975) have shown that re-
mixing (2 macroglobulin with EF
abolishes the encephalitogenic and thus
antigenic potency of the EF molecule. It
is possible that the serum-blocking effects
found in the present study may be due to
the release of oU2-macroglobulin-like com-
ponents to the circulation, which may
perform some immunoregulatory function
after tissue damage and subsequent re-
lease of normal tissue antigen. Thus, the
production of serum factor(s) which abro-
gate EF sensitivity may have important
implications in the immune response to
premalignant and malignant lesions, and
the detection of these factors may be of
practical value in the laboratory diagnosis
of such lesions.
We would like to thank the consultant and nursing
staffofthe Jessop Hospital for Women, Sheffield, for
their patience and cooperation during the course of
this study. One of us (D.J.F.) was supported by a
grant from the Yorkshire branch of the British
Cancer Research Campaign. Further assistance was
received by a grant from L.R. Industries (London).
REFERENCES
BERNARD, C. C. & LAMOUREUX, G. (1975) Inhibition
of serum of encephalitogenic activity of myelin
basic protein: nature of the serum factor respon-
sible. Cell. Immunol., 16, 182.
CASPARY, E. A. & FIELD, E. J. (1971) Specific
lymphocyte sensitisation in cancer: Is there a
common antigen in human malignant neoplasia?
Br. Med. J., ii, 613.
COATES, A. S. & CARNEGIE, P. R. (1975) Immuno-
logical cross reactivity between basic proteins of
myelin and cancer. 1. Lymphocyte tranformations
studies in immunised guinea pigs. Clin. Exp.
Immunol., 22, 16.
DICKiNSON, J. P., CASPARY, E. A. & FIELD, E. J.
(1973) A common tumour specific antigen 1.
Restriction in vivo to malignant neoplastic tissue.
Br. J. Cancer, 27, 99.
DICKINSON, J. P. & CASPARY, E. A. (1973) The
chemical nature of cancer basic protein. Br. J.
Cancer, 28 (Suppl. 1), 224.
FIELD, E. J. & CASPARY, E. A. (1970) Lymphocyte
sensitisation: an in vitro test for cancer? Lancet,
ii, 1137.
FIELD, E. J., CASPARY, E. A. & SHEPHERD, R. H. T.
(1972) Immunodiagnosis of cancer. Br. Med. J.,
iii, 641.
FIELD, E. J. & CASPARY, E. A. (1972) Lymphocyte
sensitisation in advanced malignant disease: a
study of serum lymphocyte depressive factor. Br.
J. Cancer, 26, 164.
FLAVELL, D. J. & POTTER, C. W. (1978) Cellular im-
munity to encephalitogenic factor in man, as
measured by the macrophage migration inhibition
test: the effects of serum. Br. J. Cancer, 37, 15.
FLAVELL, D. J., GOEPEL, J., POTTER, C. W. &
CARR, I. (1978) Cellular immunity to encephalito-
genic factor as measured with the macrophage
migration inhibition test during tumour induction
and growth. Br. J. Cancer, 37, 818.
FORD, W. H., CASPARY, E. A. & SHENTON, B. (1973)
Purification and properties ofa lymphocyte inhibi-
tion factor from human serum. Clin. Exp. Im-
munol., 15, 169.
GoVAN, A. D. T., HAINES, R. M., LANGLEY, F. A.,
TAYLOR, C. W. & WOODCOCK, A. S. (1969) The
histologyand cytologyofchanges in the epithelium
of the cervix uteri. J. Clin. Pathol., 22, 383.
HARRIs, R. & UIcAEJIOFO, E. 0. (1970) Tissue typing
using a routine one-step lymphocyte separation
procedure. Br. J. Haematol., 18, 229.
HUGHES, D. & PATY, D. W. (1971) Lymphocyte
sensitivity in cancer. Br. Med. J., ii, 770.
Koss, L. G. (1978) Dysplasia; a real concept or mis-
nomer. Ob8tet. Gynaecol., 51, 374.
LIGHT, P. A., PREECE, A. W. & WALDRON, H. A.
(1975) Studies with macrophage migiration in-
hibition (MMI) test in patients with malignant
disease. Clin. Exp. Immunol., 22, 279.
MCDERMOTT, J. R., CASPARY, E. A. & DICKINSON,
J. P. (1974) Antigen cross reactivity in the macro-
phage electrophoretic mobility test. A study using
cellular affinity chromatography. Clin. Exp.
Immunol., 17, 103.
PORZSOLT, F., MULBERGER, C. T. & Ax, W. (1975)
Electrophoretic mobility test (EMT). II. Is there a
correlation between the clinical diagnosis and
immunologic test for precancerous diseases?
Behring Inst. MIitt., 57, 137.
PRITCHARD, J. A. V., MOORE, J. L., SI,THERLAND,
W. H. & JOSLIN, C. A. F. (1976) Clinical assess-
ment ofthe MOD-MEM test cancer test in controls
with non-malignant diseases. Br. J. Cancer, 34, 1.
REES, R. C. & POTTER, C. W. (1973) Immune
response to adenovirus 12-induced antigens as
measured in vitro by the macrophage migration
inhibition test. Eur. J. Cancer, 8, 497.
RIOTTON, G. & CHRISTOPHERSON, W. (1973) Cytology
of the Female Genital Tract, W.H.O., Geneva.
SHELTON, J. B., POTTER, C. W. & CARR, I. (1975)
Cellular immunity to myelin basic protein in man
and in animal model systems as measured by the
macrophage migration inhibition test. Br. J.
Cancer, 31, 528.
SINGER, A., SHELTON, J., HILL, S. & POTTER, C. W.
(1975) Cellular immunity to myelin basic protein
in women with dysplasia and carcinoma in situ of
the cervix. Br. J. Obstet. Gynaecol., 82, 820.